MoleSense
MoleSense is to provide a wearable skin sensor to help monitor high-risk pregnancies.
MoleSense is to provide a wearable skin sensor to help monitor high-risk pregnancies.
MoleSense has raised $110k across 1 round. Its most recent round was a Series Unknown of $110k in Jun 2026. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
MoleSense is featured in
Similar companies
CeQur Simplicity helps people with diabetes by developing drug-delivery devices. They develop bolus insulin delivery devices that allow a person to administer insulin by clicking the buttons. They work with physicians and centers to bring technology to patients.
Calmea develops advanced contactless sensing systems that invisibly track sleep and automatically modify environment for perfect nightly rest
NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.
UNBOOUND is a medtech company and university spin-off (The Rockefeller University and University of Geneva) that specialises in human olfactory (smell) assessment.
Christina Vallgren and Marcus Palm, two physicists from CERN, co-founded Terapet along with Professor Raymond Miralbell from Geneva University Hospitals (HUG). Having demonstrated the potential of their idea, they are currently working on creating an initial version of their product for commercial release.
Axmed is a company that specializes in serving low and middle-income countries (LMICs), with the goal of enhancing their ability to purchase affordable, high-quality medicines. We collaborate only with reputable pharmaceutical companies and certified healthcare providers to expedite the availability of medications.
Babylat is an enricher device is the first automated, small-scale tabletop device for the protein enrichment of human milk.
Altiscreen is creating and producing cutting-edge, portable drug-of-abuse detection systems. With the use of our technology, law enforcement, medical professionals, and other organizations may quickly and accurately screen for drug addiction in the field.
Vivent provides growers, breeders and agrochem companies with actionable information direct from plants themselves. We help clients see how and when plants respond to changing conditions and we provide early warning (days before visual symptoms) of abiotic and biotic stressors. With better information on plant responses, growers optimise conditions and have increased yields and fruit quality. Early warning enables more effective and environmentally preferable crop protection. Plant scientists accelerate agrochem product development and improve use recommendations. Breeders can identify beneficial traits in real-time.
Multiwave develops breakthrough Magnetic Resonance Imaging and Positron Emission Tomography devices. Founded in Switzerland in March 2015, Multiwave Technologies AG has its headquarters in Geneva, Switzerland and a R&D facility in France.
Qumea provides a unique solution for discreet patient monitoring. By fusing AI and 3D radar technology, QUMEA protects the patient and disburdens the care.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.